Skip to main content Back to Top
Advertisement

11/18/2024

Mesna Injection

Products Affected - Description

    • Mesna solution for injection, Hikma, 100 mg/mL, 10 mL vial, 1 count, NDC 00143-9260-01
    • Mesna solution for injection, Sagent, 100 mg/mL, 10 mL vial, 1 count, NDC 25021-0201-10
    • Mesna solution for injection, Sagent, 100 mg/mL, 10 mL vial, 10 count, NDC 25021-0201-11

Reason for the Shortage

    • Baxter has mesna injection available. The 10 count presentations have been discontinued.
    • Fresenius Kabi has mesna available.
    • Hikma did not provide a reason for the shortage.
    • Sagent did not provide a reason for the shortage.

Available Products

    • Mesnex solution for injection, Baxter, 100 mg/mL, 10 mL vial, 1 count, NDC 00338-1305-01
    • Mesna solution for injection, Baxter, 100 mg/mL, 10 mL vial, 1 count, NDC 10019-0953-01
    • Mesna solution for injection, Fresenius Kabi, 100 mg/mL, 10 mL vial, 1 count, NDC 63323-0733-11

Estimated Resupply Dates

    • Hikma has mesna 100 mg/mL 10 mL vials on back order and the company estimates a release date of late-March to early-April 2025.
    • Sagent has mesna 100 mg/mL 10 mL vials in 1 count and 10 count on back order and the company cannot estimate a release date.

Updated

Updated November 18, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created February 21, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.

ADVERTISEMENT